Patent intelligence · WO
WO 2025252599
COMPOSÉS ACTIVATEURS DE CANAUX POTASSIQUES KV7.2/KV7.3
COMPOSÉS ACTIVATEURS DE CANAUX POTASSIQUES KV7.2/KV7.3
Patent details — WO 2025252599
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Dec 11, 2025
- Expiration
- Dec 6, 2045
- Applicant
- ANGELINI PHARMA S P A [IT]
- CPC classes
- A61K 31/ 44 A I, A61P 25/ 00 A I, A61P/2500
Quick answer
WO 2025252599 (COMPOSÉS ACTIVATEURS DE CANAUX POTASSIQUES KV7.2/KV7.3) is held by ANGELINI PHARMA S P A [IT]. Status: granted. Granted Dec 11, 2025. Expires Dec 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ANGELINI PHARMA S P A [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 44 A I, A61P 25/ 00 A I, A61P/2500
More from ANGELINI PHARMA S P A [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2025252600
COMPOSÉS ACTIVATEURS DE CANAUX POTASSIQUES KV7.2/KV7.3
granted -
AU 2024268154
NOVEL CARBOXAMIDE DERIVATIVES
granted -
IT 202300027246
Matrici farmaceutiche per il rilascio prolungato di farmaci
granted -
IT 202200024948
Composti attivatori dei canali potassio KV7.2/KV7.3
granted -
IT 202200024963
Composti attivatori dei canali potassio Kv7.2/Kv7.3
granted -
AU 2022390453
NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS
granted
Frequently asked questions
What is US patent 2025252599?
WO 2025252599 (COMPOSÉS ACTIVATEURS DE CANAUX POTASSIQUES KV7.2/KV7.3) is held by ANGELINI PHARMA S P A [IT]. Status: granted. Granted Dec 11, 2025. Expires Dec 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025252599?
ANGELINI PHARMA S P A [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does WO 2025252599 expire?
Our index shows an expiration date of Dec 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.